Patents by Inventor Chiara Bovolenta
Chiara Bovolenta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150332Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.Type: ApplicationFiled: September 19, 2023Publication date: May 9, 2024Inventors: Paolo PEVARELLO, William J. RAY, Mary HAMBY, Yaima Luzardo LIGHTFOOT, Philip JONES, Russell THOMAS, Chiara LIBERATI, Domenica TORINO, Valentina CUSANO, Francesco PISCITELLI, Ali Munaim YOUSIF, Silvia BOVOLENTA
-
Patent number: 11958839Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.Type: GrantFiled: September 22, 2021Date of Patent: April 16, 2024Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, GOLGI NEUROSCIENCES, S.R.L.Inventors: Paolo Pevarello, William J. Ray, Mary Hamby, Yaima Luzardo Lightfoot, Philip Jones, Russell Thomas, Chiara Liberati, Domenica Torino, Valentina Cusano, Francesco Piscitelli, Ali Munaim Yousif, Silvia Bovolenta
-
Publication number: 20200165629Abstract: The present invention relates to the field of the production of lentiviral vectors (LV) for gene therapy. More particularly, the invention relates to a system to obtain the stable integration of a Self Inactivating (SIN) lentiviral transfer vector into a packaging cell line. The SIN lentiviral transfer vector is integrated using a DNA fragment containing the Inverted Terminal Repeats (ITR) of Adeno Associated Virus (AAV), thus obtaining the stable producer cell line for SIN lentiviral vectors.Type: ApplicationFiled: December 20, 2016Publication date: May 28, 2020Applicant: MolMed S.p.A.Inventors: Anna STORNAIUOLO, Chiara BOVOLENTA, Fulvio MAVILIO, Gian Paolo RIZZARDI
-
Publication number: 20190284574Abstract: The present invention provides new stable packaging cell lines and producer cell lines as well as methods to obtain them, and a new method to produce lentiviral vectors using such cell lines. New methods and packaging cell lines of the invention are generated using a baculo-AAV hybrid system for stable expression of structural and regulatory lentiviral proteins, such system comprising a baculoviral backbone containing an integration cassette flanked by AAV ITR, in combination with a plasmid encoding rep protein. This system allows to obtain a stable integration of the structural and regulatory HIV-1 proteins gag/pol and rev. The system allows to obtain a first intermediate including only the structural and regulatory HIV proteins gag/pol and rev, to be used as starting point to obtain stable packaging cell lines as well as producer cell lines.Type: ApplicationFiled: October 22, 2018Publication date: September 19, 2019Applicant: MolMed, S. p. A.Inventors: Chiara BOVOLENTA, Anna STORNAIUOLO, Paolo RIZZARDI, Fulvio MAVILIO
-
Patent number: 10144937Abstract: The present invention provides new stable packaging cell lines and producer cell lines as well as methods to obtain them, and a new method to produce lentiviral vectors using such cell lines. New methods and packaging cell lines of the invention are generated using a baculo-AAV hybrid system for stable expression of structural and regulatory lentiviral proteins, such system comprising a baculoviral backbone containing an integration cassette flanked by AAV ITR, in combination with a plasmid encoding rep protein. This system allows to obtain a stable integration of the structural and regulatory HIV-1 proteins gag/pol and rev. The system allows to obtain a first intermediate including only the structural and regulatory HIV proteins gag/pol and rev, to be used as starting point to obtain stable packaging cell lines as well as producer cell lines.Type: GrantFiled: August 2, 2016Date of Patent: December 4, 2018Assignee: MolMed, S.p.A.Inventors: Chiara Bovolenta, Anna Stornaiuolo, Paolo Rizzardi, Fulvio Mavilio
-
Publication number: 20180002721Abstract: The present invention provides new stable packaging cell lines and producer cell lines as well as methods to obtain them, and a new method to produce lentiviral vectors using such cell lines. New methods and packaging cell lines of the invention are generated using a baculo-AAV hybrid system for stable expression of structural and regulatory lentiviral proteins, such system comprising a baculoviral backbone containing an integration cassette flanked by AAV ITR, in combination with a plasmid encoding rep protein. This system allows to obtain a stable integration of the structural and regulatory HIV-1 proteins gag/pol and rev. The system allows to obtain a first intermediate including only the structural and regulatory HIV proteins gag/pol and rev, to be used as starting point to obtain stable packaging cell lines as well as producer cell lines.Type: ApplicationFiled: August 2, 2016Publication date: January 4, 2018Applicant: MolMed, S.p.A.Inventors: Chiara BOVOLENTA, Anna Stornaiuolo, Paolo Rizzardi, Fulvio Mavilio
-
Patent number: 9441245Abstract: The present invention provides new stable packaging cell lines and producer cell lines as well as methods to obtain them, and a new method to produce lentiviral vectors using such cell lines. New methods and packaging cell lines of the invention are generated using a baculo-AAV hybrid system for stable expression of structural and regulatory lentiviral proteins, such system comprising a baculoviral backbone containing an integration cassette flanked by AAV ITR, in combination with a plasmid encoding rep protein. This system allows to obtain a stable integration of the structural and regulatory HIV-1 proteins gag/pol and rev. The system allows to obtain a first intermediate including only the structural and regulatory HIV proteins gag/pol and rev, to be used as starting point to obtain stable packaging cell lines as well as producer cell lines.Type: GrantFiled: September 1, 2011Date of Patent: September 13, 2016Assignee: MolMed S.p.A.Inventors: Chiara Bovolenta, Anna Stornaiuolo, Paolo Rizzardi, Fulvio Mavilio
-
Patent number: 9133481Abstract: The present invention provides a new semi-stable packaging cell line and a method to produce lentiviral vectors (LV), using the semi-stable packaging cell line. New methods and packaging cell lines of the invention are generated using a baculo-AAV hybrid system for stable expression of structural and regulatory lentiviral proteins, such system comprising a baculoviral backbone containing an integration cassette flanked by AAV ITRs, in combination with a plasmid encoding rep protein. This system allows to obtain a stable integration of the structural and regulatory HIV-1 proteins gag/pol and rev. The system allows to obtain a cell line including the structural and regulatory HIV proteins gag/pol and rev, to be used for a semi-stable LV production.Type: GrantFiled: September 1, 2011Date of Patent: September 15, 2015Assignee: MolMed S.p.A.Inventors: Chiara Bovolenta, Anna Stornaiuolo, Paolo Rizzardi, Fulvio Mavilio
-
Patent number: 8912152Abstract: A polynucleotide comprising a nucleotide sequence encoding Vif, wherein each of the amino acids corresponding to positions 127, 128, 130, 131, 132 and 142 of the amino acid sequence in FIG. 1A representing the Vif wild-type consensus sequence, are replaced with another amino acid, and wherein the nucleotide sequence does not encode the amino acid sequence shown in FIG. 2, representing the Vif sequence of the F12 non-producer variant of HIV-1.Type: GrantFiled: March 7, 2006Date of Patent: December 16, 2014Assignee: MolMed SpaInventor: Chiara Bovolenta
-
Publication number: 20140248695Abstract: The present invention relates to a new method for purification of viral vectors particularly those belonging to the Retroviridae family, which is based on the expression in the packaging cell line that produced such vectors of an exogenous gene encoding a cell surface marker. The incorporation of the cell surface marker in the viral envelope of the vector allows purification with immunological methods.Type: ApplicationFiled: October 5, 2012Publication date: September 4, 2014Applicant: MolMed, S.p.A.Inventors: Chiara Bovolenta, Anna Stornaiuolo
-
Publication number: 20140051125Abstract: The present invention provides new stable packaging cell lines and producer cell lines as well as methods to obtain them, and a new method to produce lentiviral vectors using such cell lines. New methods and packaging cell lines of the invention are generated using a baculo-AAV hybrid system for stable expression of structural and regulatory lentiviral proteins, such system comprising a baculoviral backbone containing an integration cassette flanked by AAV ITR, in combination with a plasmid encoding rep protein. This system allows to obtain a stable integration of the structural and regulatory HIV-1 proteins gag/pol and rev. The system allows to obtain a first intermediate including only the structural and regulatory HIV proteins gag/pol and rev, to be used as starting point to obtain stable packaging cell lines as well as producer cell lines.Type: ApplicationFiled: September 1, 2011Publication date: February 20, 2014Inventors: Chiara Bovolenta, Anna Stornaiuolo, Paolo Rizzardi, Fulvio Mavilio
-
Publication number: 20130164840Abstract: The present invention provides a new semi-stable packaging cell line and a method to produce lentiviral vectors (LV), using the semi-stable packaging cell line. New methods and packaging cell lines of the invention are generated using a baculo-AAV hybrid system for stable expression of structural and regulatory lentiviral proteins, such system comprising a baculoviral backbone containing an integration cassette flanked by AAV ITRs, in combination with a plasmid encoding rep protein. This system allows to obtain a stable integration of the structural and regulatory HIV-1 proteins gag/pol and rev. The system allows to obtain a cell line including the structural and regulatory HIV proteins gag/pol and rev, to be used for a semi-stable LV production.Type: ApplicationFiled: September 1, 2011Publication date: June 27, 2013Applicant: Via Olgettina, 58Inventors: Chiara Bovolenta, Anna Stornaiuolo, Paolo Rizzardi, Fulvio Mavilio
-
Publication number: 20080286248Abstract: A polynucleotide comprising a nucleotide sequence encoding Vif, wherein each of the amino acids corresponding to positions 127, 128, 130, 131, 132 and 142 of the amino acid sequence in FIG. 1A representing the Vif wild-type consensus sequence, are replaced with another amino acid, and wherein the nucleotide sequence does not encode the amino acid sequence shown in FIG. 2, representing the Vif sequence of the F12 non-producer variant of HIV-1.Type: ApplicationFiled: March 7, 2006Publication date: November 20, 2008Applicant: MolMed SpaInventor: Chiara Bovolenta